Unicycive Therapeutics (UNCY) revenue and earnings history
Unicycive Therapeutics's annual figures for 6 fiscal years, as filed with the SEC.
Over 1 years, from fiscal 2022 to fiscal 2023, revenue grew at a compound rate of −29.0% a year.
Revenue and net income, 6 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | — | −$29.5M | −$26.6M | −$31.3M | $24K | −$31.3M | $2.64M | — | — | $29.2M | — | 10-K |
| 2024ended Dec 31, 2024 | — |
The latest quarter, insider trades and fund moves: Unicycive Therapeutics (UNCY) on OQRO.
Common questions
How fast has Unicycive Therapeutics's revenue grown?
From $951K in fiscal 2022 to $675K in fiscal 2023: a compound annual growth rate of −29.0% over 1 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Unicycive Therapeutics been profitable?
It reported a net loss in 6 of the years shown (2020, 2021, 2022, 2023, 2024, 2025). The highest net income was −$2.26M in fiscal 2020.
What was Unicycive Therapeutics's free cash flow in fiscal 2025?
Where these figures come from
The SEC’s companyfacts data: every figure Unicycive Therapeutics tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
